CLEARWATER, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today reported financial results for its quarter ended June 30, 2025.
Related Questions
What were the key financial metrics (revenue, net loss, cash burn) for Q2 2025 and how do they compare to the prior quarter and same period last year?
How did sales of the Renuvion® and AYON platforms perform in the quarter, and are there any new product launches or regulatory approvals expected?
How does the company's cash position and runway look after the reported cash flow for the quarter?
What is the status of the company's ongoing FDA clearance or 510(k) submissions, and could any pending decisions materially affect future revenue?
What were the trends in gross margin and operating expenses, and what steps is management taking to improve profitability?
How might the reported results influence analyst sentiment and target price revisions for APYX in the near term?
What competitive pressures or market dynamics are influencing Apyx Medical's performance relative to peers in the minimally invasive device space?
Are there any notable changes in the company's capital structure, such as equity offerings, debt financing, or share repurchases, that could impact liquidity or dilution?
Did Apyx Medical provide any updated guidance or outlook for the remainder of 2025, and what assumptions underpin that guidance?
Did the company disclose any strategic partnerships, licensing agreements, or M&A activity that could affect its growth trajectory?